Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
≈,28255850,half-life,Population pharmacokinetic analysis identified a vemurafenib half-life of ≈57 h and elimination appears to be predominantly via the hepatic route.,Clinical Pharmacokinetics of Vemurafenib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28255850/),h,57,6199,DB00697,Tizanidine
,9698954,Elimination half-lives,"Elimination half-lives of TZD in CSF were 15 min and 152 min, respectively.","Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698954/),min,15,28834,DB00697,Tizanidine
,9698954,Elimination half-lives,"Elimination half-lives of TZD in CSF were 15 min and 152 min, respectively.","Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698954/),min,152,28835,DB00697,Tizanidine
,9698954,Clearance,Clearance of TZD from lumbar CSF was 0.48 ml/min.,"Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698954/),[ml] / [min],0.48,28836,DB00697,Tizanidine
,6617726,absorption half-life,"The drug had a mean absorption half-life of 0.30 +/- 0.155 h following a mean lagtime of 0.361 +/- 0.118 h, and a mean terminal elimination half-life of 4.16 +/- 2.06 h.",Tizanidine--initial pharmacokinetic studies in patients with spasticity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617726/),h,0.30,32430,DB00697,Tizanidine
,6617726,lagtime,"The drug had a mean absorption half-life of 0.30 +/- 0.155 h following a mean lagtime of 0.361 +/- 0.118 h, and a mean terminal elimination half-life of 4.16 +/- 2.06 h.",Tizanidine--initial pharmacokinetic studies in patients with spasticity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617726/),h,0.361,32431,DB00697,Tizanidine
,6617726,terminal elimination half-life,"The drug had a mean absorption half-life of 0.30 +/- 0.155 h following a mean lagtime of 0.361 +/- 0.118 h, and a mean terminal elimination half-life of 4.16 +/- 2.06 h.",Tizanidine--initial pharmacokinetic studies in patients with spasticity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617726/),h,4.16,32432,DB00697,Tizanidine
,23380428,"peak plasma concentration, Cmax","The average bioavailability measures and pharmacokinetic parameters of the two tizanidine tablets were as follows: peak plasma concentration, Cmax, was 1.21 ± 0.84 ng/ml and 1.28 ± 1.11 ng/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[ng] / [ml],1.21,47473,DB00697,Tizanidine
,23380428,"peak plasma concentration, Cmax","The average bioavailability measures and pharmacokinetic parameters of the two tizanidine tablets were as follows: peak plasma concentration, Cmax, was 1.21 ± 0.84 ng/ml and 1.28 ± 1.11 ng/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[ng] / [ml],1.28,47474,DB00697,Tizanidine
,23380428,time to peak plasma concentrations tmax,"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,0.83,47475,DB00697,Tizanidine
,23380428,time to peak plasma concentrations tmax,"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,1.01,47476,DB00697,Tizanidine
,23380428,plasma half-life (t1/2),"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,1.20,47477,DB00697,Tizanidine
,23380428,plasma half-life (t1/2),"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,1.29,47478,DB00697,Tizanidine
,23380428,area under the plasma concentration-time profiles AUC0→last,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.53,47479,DB00697,Tizanidine
,23380428,area under the plasma concentration-time profiles AUC0→last,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.46,47480,DB00697,Tizanidine
,23380428,AUC0→∞were,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.81,47481,DB00697,Tizanidine
,23380428,AUC0→∞were,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.75,47482,DB00697,Tizanidine
,23380428,mean residence time (MRT),The mean residence time (MRT) values were 2.16 ± 0.693 hours and 2.33 ± 0.65 hours.,Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,2.16,47483,DB00697,Tizanidine
,23380428,mean residence time (MRT),The mean residence time (MRT) values were 2.16 ± 0.693 hours and 2.33 ± 0.65 hours.,Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,2.33,47484,DB00697,Tizanidine
,24680961,oral bioavailability,Tizanidine HCl is a skeletal muscle relaxant that suffers from extensive hepatic metabolism resulting in 34-40% oral bioavailability.,Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24680961/),%,34-40,52302,DB00697,Tizanidine
,24680961,half-life,It also suffers from short half-life (2.1-4.2h) that necessitates frequent administration thus reducing patient compliance.,Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24680961/),h,2.1-4.2,52303,DB00697,Tizanidine
,24680961,encapsulation efficiency,It provided encapsulation efficiency of 56.5% and controlled tizanidine release over 8h.,Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24680961/),%,56.5,52304,DB00697,Tizanidine
,28156169,encapsulation efficiency,"It exhibited encapsulation efficiency of 52.39%, mean diameter of 150.33 nm, controlled drug release over 8 h and good permeation characteristics.","Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of tizanidine HCl: preparation, in vitro and in vivo performance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156169/),%,52.39,61544,DB00697,Tizanidine
,28156169,t1/2,The pharmacokinetic study revealed that the transfersomal formulation successively enhanced the bioavailability of TIZ by about 2.18-fold and increased t1/2 to about 10 h as compared to oral solution.,"Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of tizanidine HCl: preparation, in vitro and in vivo performance. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156169/),h,10,61545,DB00697,Tizanidine
,24120717,Metabolic clearance,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],5.9,71230,DB00697,Tizanidine
,24120717,Metabolic clearance,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],8.1 - 10.9,71231,DB00697,Tizanidine
,24120717,renal clearances,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],0.040,71232,DB00697,Tizanidine
,24120717,renal clearances,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],0.047 - 0.055,71233,DB00697,Tizanidine
,32911847,flow rate,"The mobile phase composition was a mixture of 0.1% diethylamine/acetonitrile (70:30, v/v) at pH 8 in an isocratic mode at flow rate was 1.0 mL/min.",Development and Validation of an HPLC-UV Detection Assay for the Determination of Clonidine in Mouse Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32911847/),[ml] / [min],1.0,81824,DB00697,Tizanidine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,1.5,84231,DB00697,Tizanidine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,4,84232,DB00697,Tizanidine
,17617289,C(max),"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),[ng] / [ml],2.7,91385,DB00697,Tizanidine
,17617289,C(max),"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),[ng] / [ml],4.0,91386,DB00697,Tizanidine
,17617289,TmaX,"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),h,2.6,91387,DB00697,Tizanidine
,17617289,TmaX,"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),h,1.2,91388,DB00697,Tizanidine
,24085590,relative bioavailability,"The relative bioavailability of the different dosages of intranasal formulation were 1.29, 1.93, and 4.23 for 1, 2, and 4 mg intranasal administration, respectively.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),,1.29,122503,DB00697,Tizanidine
,24085590,relative bioavailability,"The relative bioavailability of the different dosages of intranasal formulation were 1.29, 1.93, and 4.23 for 1, 2, and 4 mg intranasal administration, respectively.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),,1.93,122504,DB00697,Tizanidine
,24085590,relative bioavailability,"The relative bioavailability of the different dosages of intranasal formulation were 1.29, 1.93, and 4.23 for 1, 2, and 4 mg intranasal administration, respectively.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),,4.23,122505,DB00697,Tizanidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,0.99,122506,DB00697,Tizanidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,0.43,122507,DB00697,Tizanidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,0.63,122508,DB00697,Tizanidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,1.13,122509,DB00697,Tizanidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,1.30,122510,DB00697,Tizanidine
,3447935,bioavailability,"Tizanidine was rapidly and almost completely absorbed from the gastrointestinal tract, although the estimated bioavailability was only 21% due to extensive first-pass metabolism.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),%,21,122983,DB00697,Tizanidine
,3447935,terminal half-lives,"The terminal half-lives of tizanidine and radioactivity were ca 3 hr and 61 hr, respectively, and 76%-77% of the administered radioactivity was recovered within 120 hr.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),h,3,122984,DB00697,Tizanidine
,3447935,terminal half-lives,"The terminal half-lives of tizanidine and radioactivity were ca 3 hr and 61 hr, respectively, and 76%-77% of the administered radioactivity was recovered within 120 hr.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),h,61,122985,DB00697,Tizanidine
,3447935,effective half-life,"The degree of accumulation of radioactivity, unlike that of parent drug, was inconsistent with the terminal half-life, but instead implied a shorter effective half-life of ca. 16 hr.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),h,16,122986,DB00697,Tizanidine
,19789372,peak plasma concentration,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[ng] / [ml],1.8,132457,DB00697,Tizanidine
,19789372,peak plasma concentration,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[ng] / [ml],5.3,132458,DB00697,Tizanidine
,19789372,area under the curve,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[h·ng] / [ml],4.5,132459,DB00697,Tizanidine
,19789372,area under the curve,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[h·ng] / [ml],15.4,132460,DB00697,Tizanidine
,19789372,half-life,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),h,1.3,132461,DB00697,Tizanidine
,19789372,half-life,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),h,1.8,132462,DB00697,Tizanidine
,17062304,T(max),The median T(max) increased significantly from 1.41 to 3.0 hours (P < 0.001).,Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062304/),h,1.41,135858,DB00697,Tizanidine
,17062304,T(max),The median T(max) increased significantly from 1.41 to 3.0 hours (P < 0.001).,Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062304/),h,3.0,135859,DB00697,Tizanidine
,18197403,K(i) (inhibitor constant),Celecoxib was found to be a moderately potent competitive inhibitor of CYP1A2 in vitro with a K(i) (inhibitor constant) of 25.4 microM.,Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197403/),μM,25.4,155529,DB00697,Tizanidine
,17618427,IC(50),Tolfenamic acid strongly inhibited phenacetin-O-deethylation in vitro (IC(50) 1.8 microM without albumin).,Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17618427/),μM,1.8,164396,DB00697,Tizanidine
exceeded,17618427,IC(50),Albumin decreased its inhibitory effect in a concentration-dependent manner; the IC(50) exceeded 100 microM with 10 mg/ml of albumin.,Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17618427/),μM,100,164397,DB00697,Tizanidine
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.5,187837,DB00697,Tizanidine
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.8,187838,DB00697,Tizanidine
,29566073,AUC 0-t,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],6655.64,196390,DB00697,Tizanidine
,29566073,AUC 0-t,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],6538.99,196391,DB00697,Tizanidine
,29566073,Cmax,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],436.98,196392,DB00697,Tizanidine
,29566073,Cmax,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],411.33,196393,DB00697,Tizanidine
,29566073,half-life,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),h,9.91,196394,DB00697,Tizanidine
,29566073,half-life,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),h,2.51,196395,DB00697,Tizanidine
,29566073,AUC 0-t,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],1043.4,196396,DB00697,Tizanidine
,29566073,AUC 0-t,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],149.1,196397,DB00697,Tizanidine
,29566073,Cmax,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],91.92,196398,DB00697,Tizanidine
,29566073,Cmax,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],42.29,196399,DB00697,Tizanidine
,16810637,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Quantification of tizanidine in human plasma by liquid chromatography coupled to tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16810637/),min,2.5,203985,DB00697,Tizanidine
,2600869,plasma half-life,The plasma half-life was 2.7 +/- 0.06 hours.,Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600869/),h,2.7,236104,DB00697,Tizanidine
,29403722,recoveries,The intra- and inter-day precision values were below 13% and the recoveries were from 74.47% to 83.20% at three quality control levels.,Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403722/),%,74.47,255724,DB00697,Tizanidine
,29403722,recoveries,The intra- and inter-day precision values were below 13% and the recoveries were from 74.47% to 83.20% at three quality control levels.,Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403722/),%,83.20,255725,DB00697,Tizanidine
,30221568,enhancement ratio (ER,The permeation parameters of the selected bilosomes were compared to the unformulated drug and it was shown that TZN-B24 exhibited the highest enhancement ratio (ER = 8.8).,Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30221568/),,8.8,272021,DB00697,Tizanidine
,30221568,VS,The mathematical model used for the optimization was validated by comparing the predicted values of the EE (82.3%) and the VS (165.8 nm) with the experimental values of EE = 84.42% and of VS = 161.95 nm.,Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30221568/),,165,272022,DB00697,Tizanidine
,30221568,VS,The mathematical model used for the optimization was validated by comparing the predicted values of the EE (82.3%) and the VS (165.8 nm) with the experimental values of EE = 84.42% and of VS = 161.95 nm.,Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30221568/),nm,161.95,272023,DB00697,Tizanidine
,31103968,t1/2,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,2.51,274032,DB00697,Tizanidine
,31103968,t1/2,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,10,274033,DB00697,Tizanidine
,31103968,Cmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),[ng] / [ml],42.3,274034,DB00697,Tizanidine
,31103968,Cmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),[ng] / [ml],105,274035,DB00697,Tizanidine
,31103968,tmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,2,274036,DB00697,Tizanidine
,31103968,tmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,6,274037,DB00697,Tizanidine
